XENE Xenon Pharmaceuticals Inc

Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
EN
08/10/2020

Underlying

XENEXenon Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
11/07/25 November 7, 2025 1 EN
 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon to Present at Upcoming Investor Conferences

Xenon to Present at Upcoming Investor Conferences VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ConferenceThursday, November 13, 2025 at 3:20 PM ET Jefferies Global Healthcare Conference in London onWednesday, November 19, 2025 at 11:30 AM G...

November 6, 2025 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
RNG RINGCENTRAL INC. CLASS A
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
ROKU ROKU INC. CLASS A
DDOG DATADOG INC CLASS A
FUBO FUBOTV
PLTR PALANTIR TECHNOLOGIES
NUVB NUVATION BIO INC (A)
TTD THE TRADE DESK
PAY INC.
SLDB PAYMENTUS HLDGS INC
SOLID BIOSCIENCES INC
11/04/25 November 4, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
11/04/25 November 4, 2025 1 EN
 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon Reports Third Quarter 2025 Financial Results & Business Update

Xenon Reports Third Quarter 2025 Financial Results & Business Update – Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmac...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch